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You are renowned throughout the city-state for your great feats of endurance. 
Whereas those ninnies in Homer’s Odyssey are always stopping to eat and 
sleep in desperate hopes of restoring themselves to “form,” terrified as they are 
of the ravages of time, you, without even thinking of food, once had a long, 
winding, and extremely demanding discussion with a number of men much 
younger than you that lasted over a whole night! (The young Polemarchus 
had enticed you to come to his house with the promise of supper, among 
other distractions [Republic, 328a]; but things more permanent and beauti-
ful freed even the young men from the tyranny of the belly. Poor Odysseus: 
“Belly must be filled” [Odyssey, bk. 7]. How the poets lie!) Then there is the 
story of how, after a night of feasting and drinking and story-telling about 
love—and after Alcibiades, and then a number of other drunks, broke into 
the party and made everybody drink yet more!—you went off, fresh as could 
be, and spent the whole next day as was your wont, discussing with young 
men at the lyceum (Symposium, 223d). Neither Aristophanes nor Agathon, 
try as they did, could stay up with you. How do you do it?
The secret? Well, what would we think if it were…modafinil?1
“Professor’s Little Helper” is the title of a commentary published in decem-
ber 2007 in the journal Nature by Cambridge University scientists Barbara 
Sahakian and Sharon Morein-Zamir. The two discuss the “off-label” use of 
cognitive-enhancing drugs and remark that, “[i]n academia, we know that a 
number of our colleagues…already use modafinil to counteract the effects of 
jetlag, to enhance productivity or mental energy, or to deal with demanding 
and important intellectual challenges” (Sahakian and Morein-Zamir 2007, 
1158). It might be thought that this should hardly count as news—the use 
of the methylphenidate ritalin and amphetamine Adderall by cramming 
college students comes as no surprise, even if it has not lost the power to 
134 Socrates on Drugs
© Equinox Publishing Ltd. 2008
shock—but news this story became. Among other examples: Only days later, 
The Chronicle of Higher Education invited comments online (see the news 
blog “Brain-Boosting drugs Hit the Faculty Lounge”). Nature both opened a 
“public forum” online (see, “Would you boost your brain power?”) and con-
ducted an anonymous online survey to determine the prevalence of off-label 
use of such drugs. The journal also published multiple letters in response to 
Sahakian and Morein-Zamir in its January 31, 2008 issue.2 Then, in March, 
The New York Times took notice with an article in its Week-in-review entitled 
“Brain Enhancement Is Wrong, right?” According to The Times, “an era of 
doping may be looming in academia, and it has ignited a debate about policy 
and ethics that in some ways echoes the national controversy over perform-
ance enhancement accusations against elite athletes like Barry Bonds and 
roger Clemens…” (Carey 2008).3
All these articles and discussions are well worth reading; the conceit of 
Socrates on drugs is taken, in fact, from the Nature public forum.4 It might 
be wondered, however, whether the questions and concerns that these arti-
cles and discussions raise go to the heart of the matter. The questions and 
concerns that come up again and again are safety (for example, whether there 
is a risk of harmful side-effects, or a danger of addiction); fairness or justice 
(would the drugs be available to all? would disparities increase?); whether 
there would be coercive pressure to use such drugs—and have our children 
use such drugs—should “everyone” be doing it in the most competitive, high-
ly-compensated professions and in the schools that prepare students for these 
professions;5 whether the use of such drugs is in fact unprecedented (think of 
coffee, tea, and nicotine), or in other words “only” different in degree rather 
than kind from the consumption of more familiar substances;6 and finally 
whether pharmacological enhancements are different in a morally significant 
way from more mundane forms of “life enhancers” that some people have the 
fortune to benefit from (like tutors or test-preparation courses).7 These are 
surely important questions to ask, and the answers are not obvious.8 But there 
are other questions that might be considered just as or even more important 
and that find expression less frequently, perhaps because they are difficult to 
articulate, and because some involve considerations that our individualistic, 
capitalist society has become largely blind to.
To return to academics on drugs: Why devote one’s life to study? Why seek 
knowledge as a profession or vocation? Surely “academic success” should be, 
if it is not always, a secondary consideration. (If people go into academics 
with the principal aim of becoming academic “superstars,” do they go into it 
for the right reason? Or is there, after all, nothing truly sacred in the “sacred 
Bernard G. Prusak 135
© Equinox Publishing Ltd. 2008
groves of academe,” such that one may behave there as one wishes?9) Most 
academics hold Ph.d.’s: doctorates of philosophy, which etymologically means 
love of wisdom, not simply knowledge. And wisdom has to do with living well 
as human beings. Yes, it may be natural to human beings, as Aristotle remarks 
at the beginning of his Metaphysics, to reach out to know; and knowledge 
does appear to be a basic human good.10 Further, cognitive-enhancing drugs 
may serve and advance the accumulation and discovery of knowledge. But 
does knowledge so discovered serve the person who discovered it, or does he 
or she begin to serve it? In other, more dramatic terms, has such a person 
made him or herself a slave to the discovery of knowledge—to change the 
terms, but keep the drama, made knowledge an idol that he or she serves, to 
the sacrifice of his or her humanity?
The claim that a human being risks sacrificing or distorting or otherwise 
damaging his or her “humanity” in doing this or that—in other words, that 
there is something “essentially human” at stake in a practice—obviously needs 
clarification and elaboration, and needs it quickly. The claim needs clarifica-
tion and elaboration since it is undeniably vague; it needs clarification and 
elaboration quickly lest it be simply dismissed as “nostalgic, sentimentalized” 
nonsense, another instance of “right-wing arguments that have been made for 
centuries in the face of anything new”—which was the judgment of a blogger 
on a recent article in The New Republic by Leon kass and Eric Cohen on the 
use of biotechnical enhancements in sports.11 kass and Cohen make such a 
claim; what they mean by it deserves at least attention.
kass is a notoriously controversial figure in the debate on enhancement 
and in bioethics generally, no doubt in part because of his occasional rhetori-
cal excesses. Another reason, though, may be that he challenges the dogma, 
whether true or false, of our time and place that the way to happiness or 
fulfillment is to do what I want, as I want, when I want—and who is anyone 
to tell me that I could be wrong? kass’s principal criticism of the use of biotech-
nology “beyond enhancement,” whether for improved cognition, mood, or 
strength, is that “[h]uman experience under biological intervention becomes 
increasingly mediated by unintelligible forces and vehicles” (kass 2003, 22), 
such that the human being becomes “less doer and more done-to” and “[h]is 
doings become, in a crucial sense, less ‘his own’” (kass and Cohen 2008, 36). 
In other words, we become fields where the drugs we take express themselves; 
our achievements become effects, no longer of the exertions of our character 
and cultivation of our native gifts, but of the armamentarium of drugs that 
happens to be at our disposal. Whereas kass claims:
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[I]f human flourishing means not just the accumulation of external 
achievements and a full curriculum vitae, but a life-long being-at-work 
exercising one’s human powers well and without great impediment, 
our genuine happiness requires that there be little gap, if any, between 
the dancer and the dance… (kass 2003, 23)
There are yet further important questions to raise about cognitive-enhanc-
ing drugs. For example, is it the role of medical professionals to supply such 
drugs to “patients”? If we answer yes, would this mean a significant change 
in the nature of the institution of medicine—which is arguably already in a 
state of conceptual confusion (Caplan, McCartney, and Sisti 2004)—and, if 
so, would this be a change for the better or worse? Also, do we, as a society, 
really want pharmaceutical companies to be developing new classes of drugs 
without a disease in mind, but instead with the aim of “augment[ing] normal 
encoding mechanisms” (Chatterjee 2006, 110)? It is happening already. For, 
though most of the earth’s people still lack basic healthcare, these companies, 
which make staggering profits as it is, “have significant economic incentives 
to expand their markets to healthy individuals” (Chatterjee 2006, 112). The 
poor can’t pay. That healthy academics, many of whom lean politically to 
the left, would provide these companies a new market—where is that gadfly 
Socrates when we need him?
The editors have asked our contributors to this second iteration of “Over-
heard in the Academy” to take up and enrich or rebut these reflections.
Notes
1. Modafinil is marketed under the label Provigil by, remarkably enough, the bi-
opharmaceutical company Cephalon. (Cephalus is the name of Polemarchus’s 
father. The name means “head.”) According to the manufacturer, “Provigil is a 
prescription medicine used to improve wakefulness in adults who experience 
excessive sleepiness (ES) due to one of the following diagnosed sleep disorders: 
obstructive sleep apnea (OSA), shift work sleep disorder [SWSd], or narcolepsy” 
(see www.provigil.com). The U.S. armed services are apparently studying mo-
dafinil intensively (Chatterjee 2006, 110).
2. To quote a bit from two of the more provocative letters, Nick Bostrom writes:
 With the cockcrow of enhancement medicine, we need to retool our regulatory paradigm. 
It is not only special occupations such as military commandos and air-traffic controllers 
that would benefit from good enhancement drugs. Other jobs are just as important and 
intellectually taxing—including the jobs of many scientists and academics. Anything that 
can help our brains deal better with the complex challenges of the twenty-first century is 
to be not only welcomed but actively sought. But it will require substantial investment 
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to develop interventions that are both safe and effective in long-term use (Bostrom 2008, 
520).
 To which John Harris and Muireann Quigley add:
 Science and technology will continue to generate all sorts of new enhancers, and the 
quest for enhancement is not necessarily unfair or unethical. We humans are inveter-
ate enhancers, striving to increase our intelligence and to improve our memory and 
powers of perception…. We must press for wider and more equitable access, turning 
our backs neither on technology nor on improving the human condition (Harris and 
Quigley 2008, 521).
3. The analogy of doping in academia to doping in sports is often invoked, but 
sometimes only to be rejected. For example, “a phil prof” contributing to the 
Chronicle blog writes that “the analogy with baseball is silly. research is a joint 
effort, whether one realizes it or not. Another’s good research helps us all. If you 
need to be hopped up on something, I won’t worry that you’ll break a record be-
fore me….” See http://chronicle.com/news/article/3673/brain-boosting-drugs-
hit-the-faculty-lounge, number 28.
4. A blogger identifying himself as Nicolau Werneck writes: “We must change all 
of this, the tests and the competitions in science and teaching. That’s not what 
science is all about! Can you imagine Socrates taking ritalin? What would be 
his motivation? I bet he would drink conium before that.” See http://network.
nature.com/forums/naturenewsandopinion/816?page=4.
5. As Michael J. Sandel nicely observes:
 Unlike the drugs of the sixties and seventies [for example: marijuana and LSd], rita-
lin and Adderall are not for checking out but for buckling down, not for beholding the 
world and taking it in, but for molding the world and fitting in…. The steroids and 
stimulants that figure in the enhancement debate are not a source of recreation but a 
bid for compliance, a way of answering a competitive society’s demand to improve our 
performance and perfect our nature (Sandel 2007, 60–61).
6. It is worth noting that not all drugs that have the same effects, and so could have 
the same uses, necessarily figure in the same ways in human culture. For example, 
coffee may be used as a stimulant in order to “buckle down,” but it may also be 
used, and often is, as a way to “check out” from the pressures of work. It shouldn’t 
be forgotten that people go to cafés to socialize or read!
7. A blogger identifying himself as Charles Eaton writes:
 As to the bug-bear of “competitive advantage,” that is not a public health issue at all 
but a personal ethical and philosophical question. Today I will give my 7-year-old 
granddaughter a piano lesson, lead her in a chemistry experiment, listen to her sums, 
and encourage her to enter any new words of her vocabulary into her personal diction-
ary. do I intend to nurture her toward a “competitive advantage”? Oh, you bet!
 See http://network.nature.com/forums/naturenewsandopinion/816?page=2.
8. See for a synthesis of these questions and concerns Chatterjee 2006.
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9. Plato’s school or “academy” was located in and took its name from the sacred 
groves of Athena.
10. It is good to know; even denying it depends on acknowledging it and seeking to 
know.
11. See the comments of “JSmith125” (#2 of 14) at http://www.tnr.com/talkback.
html?id=ea669633-6736-4302-ac23-cd967bbe64f4.
References
Bostrom, Nick
2008 drugs Can Be Used to Treat More Than disease. Nature 451/7178: 520. 
doi:10.1038/451520b
Caplan, Arthur L., James M. McCartney, and dominic A. Sisti, eds.
2004 Health, Disease, and Illness: Concepts in Medicine. Washington, dC: Geor-
getown University Press.
Carey, Benedict
2008 Brain Enhancement Is Wrong, right? New York Times, March 9, Week-in-
review.
Chatterjee, Anjan
2006 The Promise and Predicament of Cosmetic Neurology. Journal of Medical 
Ethics 32: 110–113. doi:10.1136/jme.2005.013599
Harris, John and Muireann Quigley
2008 Humans Have Always Tried to Improve Their Condition. Nature 
451(7178): 521. doi:10.1038/451521b
kass, Leon r.
2003 Ageless Bodies, Happy Souls. The New Atlantis 1: 9–28.
kass, Leon r. and Eric Cohen.
2008 For the Love of the Game. The New Republic, March 26.
Sahakian, Barbara and Sharon Morein-Zamir
2007 Professor’s Little Helper. Nature 450(7173): 1157–1159. 
doi:10.1038/4501157a
Sandel, Michael J.
2007 The Case against Perfection. Cambridge, MA: Harvard University Press.
